Prevalence of RFC1-mediated spinocerebellar ataxia in a North American ataxia cohort
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received November 7, 2019
- Accepted in final form March 15, 2020
- First Published May 20, 2020.
Author Disclosures
- Dona Aboud Syriani,
- Darice Wong, PhD,
- Sameer Andani, BS,
- Claudio M. De Gusmao, MD,
- Yuanming Mao, BS,
- May Sanyoura, PhD,
- Giacomo Glotzer,
- Paul J. Lockhart, PhD,
- Sharon Hassin-Baer, MD,
- Vikram Khurana, MD, PhD,
- Christopher M. Gomez, MD, PhD,
- Susan Perlman, MD,
- Soma Das, PhD and
- Brent L. Fogel, MD, PhD
- Dona Aboud Syriani,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Darice Wong, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sameer Andani, BS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Claudio M. De Gusmao, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Research support from the National Ataxia Foundation
NONE
NONE
NONE
NONE
Research support from the National Ataxia Foundation; Research Support from the Ataxia-Teleangiectasia Children's Project
NONE
NONE
NONE
NONE
NONE
NONE
- Yuanming Mao, BS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- May Sanyoura, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Giacomo Glotzer,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Paul J. Lockhart, PhD,
NONE
NONE
NONE
(1) Genetics Research International, Editorial board member, 2010-2017 (2) Open Access (OA) Genetics, Editorial board member, 2012-2016 (3) Journal of Neurochemistry, Handling Editor, 2018-current
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1. National Health and Medical Research Council (Australia) Project grant APP1144724 2018-2020. 2. National Health and Medical Research Council (Australia) Project grant APP1128933 2017-2018. 3. National Health and Medical Research Council (Australia) Project grant APP1098255 2016-2020. 4. National Health and Medical Research Council (Australia) Project grant APP1144724 2018-2020.
NONE
Michael J Fox Foundation, Project Grant 12173, 2016-2017
NONE
NONE
NONE
NONE
NONE
NONE
- Sharon Hassin-Baer, MD,
NONE
NONE
Funding for travel or speaker honoraria FROM ABBVIE, MEDISON, ALLERGAN, IBSEN,
NONE
NONE
NONE
NONE
I have received consultancy fees from Abbvie, TEVA, ALLERGAN and Medtronic.
NONE
NONE
NONE
NONE
Chief scientist of the Ministry of Commerce and science: study on mild cognitive impairment in Parkinson's disease
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Vikram Khurana, MD, PhD,
Co-Founder, equity holding and adviser in Yumanity Theraepeutics (myself and spouse) Scientific Advisory Board, Enclear Therapies
NONE
NONE
NONE
(1) Yeast to human stem cell discovery platform for neurodegenerative proteinopathies (2) Transposenet: Cross-species tool for mapping molecular networks
NONE
Yumanity Therapeutics, Senior Adviser, 4
1) Yumanity Therapeutics 2) Enclear Therapies 3) Lundbeck 4) Seelos 5) Moderna 6) Astellas 7) DSI
NONE
NONE
NONE
Yumanity Therapeutics (spouse's employer)
1) National Institutes of Health (NINDS), R21 NS112858 , PI, 2 year 2) Department of Defense, W81XWH1910695, PI, 3 year
Brigham and Women's Hospital
New York Stem Cell Foundation Multiple System Atrophy Coalition National Ataxia Foundation Harvard Neurodiscovery Center
NONE
1) Engineered Human Stem-Cell Lines, Yumanity Therapeutics 2) Engineered U20S Cell lines, Yumanity Therapeutics
As above (see patent applications)
NONE
NONE
NONE
- Christopher M. Gomez, MD, PhD,
NONE
NONE
NONE
NONE
PCT/US16/45492 Priority date: 08/04/2015 Status:awarded
NONE
NONE
pending APDM
NONE
NONE
NONE
Biogen Pfizer
NIH/NINDS R01NS082788-06 NIH/NINDS R01NS082788
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Susan Perlman, MD,
(1) National Ataxia Foundation Medical Research Advisory Board.
NONE
NONE
NONE
NONE
NONE
(1) UCLA Medical Center, fulltime staff physician
NONE
NONE
NONE
NONE
(1) Santhera Phamaceuticals (2) Edison Pharmaceuticals (3) Viropharma Pharmaceuticals (4) Horizon Pharmaceuticals (5) Reata Pharmaceuticals (6) Biohaven Pharmaceuticals (7) Teva Pharmaceuticals (8) Takeda Pharmaceuticals (9) Cadent Pharmaceuticals
(1) ARRAS funding via the RDN-CRC, subcontracted from University of Florida, PI at UCLA for the study 2009-2011
NONE
(1) Friedreich Ataxia Research Alliance (2) National Ataxia Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Soma Das, PhD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH/NHGRI, 2 U41 HG006834-04, 09/23/13 Â 07/31/21, ÂClinical Genome ResourceÂ, Soma Das, Ph.D., Co-Investigator (10% effort); H. Rehm, PhD., Principal Investigator, Annual direct cost: $1,803,751
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Brent L. Fogel, MD, PhD
NONE
NONE
1. American Academy of Neurology, Speaker Honoraria 2. National Ataxia Foundation, Travel
1. Neurology:Genetics, Editorial Board, 2 years 2. Neurology Today, Editorial Board, 4 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1. NIH/NINDS R01 NS082094 (PI Fogel) 04/2013 - 03/2019
NONE
National Ataxia Foundation (PI Fogel) 1/2019-12/2022
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (D.A.S., D.W., Y.M., S.P., B.L.F.), Program in Neurogenetics, David Geffen School of Medicine, University of California, Los Angeles; Department of Neurology (D.W., B.L.F.), Clinical Neurogenomics Research Center, David Geffen School of Medicine, University of California, Los Angeles; Department of Human Genetics (S.A., M.S., S.D.), University of Chicago, IL; Department of Neurology (C.M.D.G., V.K.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Department of Neurology (G.G., C.M.G.), University of Chicago, IL; Bruce Lefroy Centre (P.J.L.), Murdoch Children's Research Institute; Department of Paediatrics (P.J.L.), University of Melbourne, Parkville, Australia; Sackler Faculty of Medicine (S.H.-B.), Tel-Aviv University, Tel-Aviv, Israel; and Department of Human Genetics (B.L.F.), David Geffen School of Medicine, University of California, Los Angeles.
- Correspondence
Dr. Fogel bfogel{at}ucla.edu or Dr. Das sdas{at}bsd.uchicago.edu
Article usage
Cited By...
Letters: Rapid online correspondence
NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.ng.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.